<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325763</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-III-05</org_study_id>
    <nct_id>NCT04325763</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)</brief_title>
  <official_title>A Randomized, Double-blind and Imitation, Placebo Parallel Control, Multicentre Phase III Study of TQB2450 With or Without Anlotinib as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Have Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, double-dummy,placebo parallel controlled,
      multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or
      without anlotinib compared with placebo as consolidation treatment in subjects with locally
      advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after
      prior concurrent/sequential chemoradiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) evaluated by Independent Review Committee(IRC)</measure>
    <time_frame>up to 33 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS evaluated by Investigator</measure>
    <time_frame>up to 33 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 33 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 33 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response（DOR）</measure>
    <time_frame>up to 33 months</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS rate at month 6</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The percentage of PFS at month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS rate at month 12</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The percentage of PFS at month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers, such as PD-L1 expression, etc.</measure>
    <time_frame>up to 33 months</time_frame>
    <description>Tissue samples were collected during the screening period for pd-l1 analysis. Blood samples were collected for Tumor Mutation Burden (TMB) test before enrollment (within 7 days before medication) and after exit (±3 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, such as the incidence of ADA</measure>
    <time_frame>on day 1, 42, 105, 189 and 90 days after the last administration.</time_frame>
    <description>Degree of the immune response caused by the drug.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">315</enrollment>
  <condition>Stage III Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQB2450+Anlotinib(blank)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQB2450(blank)+Anlotinib(blank)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
    <arm_group_label>TQB2450+Anlotinib(blank)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>a multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450(blank)</intervention_name>
    <description>Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day</description>
    <arm_group_label>TQB2450(blank)+Anlotinib(blank)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib(blank)</intervention_name>
    <description>Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
    <arm_group_label>TQB2450(blank)+Anlotinib(blank)</arm_group_label>
    <arm_group_label>TQB2450+Anlotinib(blank)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-75 years old ; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
             1; Life expectancy ≥ 3 months.

          2. Histologically or cytologically confirmed unresectable (Stage III) Non-Small Cell Lung
             Cancer.

          3. At least has one measurable lesion before radiotherapy.

          4. At least has one type of platinum-containing chemotherapy, Absence of progression
             after concurrent/sequential chemoradiotherapy.

          5. Adequate laboratory indicators.

          6. No pregnant or breastfeeding women, and a negative pregnancy test.

          7. Understood and signed an informed consent form.

        Exclusion Criteria:

          1. Squamous cell carcinoma meets following conditions should be excluded:

               1. Cavernous lung cancer.

               2. Has hemoptysis and maximum daily hemoptysis volume ≥ 2.5ml within 1 month before
                  the first administration.

          2. Has received anti-angiogenic drugs or other PD-1 / PD-L1 / CTLA-4 antibody therapy or
             other immunotherapy against PD-1 / PD-L1 / CTLA-4.

          3. Severe hypersensitivity occurs after administration of other monoclonal antibodies.

          4. Diagnosed and/or treated additional malignancy within 5 years with the exception of
             cured basal cell carcinoma of skin ,carcinoma in situ of prostate,and carcinoma in
             situ of cervix.

          5. Pathologically confirmed mixed small cell and non-small cell lung cancer.

          6. EGFR gene mutations.

          7. Has any active autoimmune disease or history of autoimmune disease.

          8. After the early stage of chemoradiotherapy, the treatment toxicity ≥ grade 2 is not
             fully alleviated.

          9. Has ≥grade 2 pneumonia.

         10. Immunosuppressant or systemic or absorbable local hormone therapy is required to
             achieve the aim of immunosuppression (dose &amp;gt; 10mg/ day prednisone or other
             therapeutic hormones) and is still used within 2 weeks after the first administration.

         11. Has multiple factors affecting oral medication.

         12. Has active bleeding or a persistent decrease in hemoglobin.

         13. Has any bleeding or bleeding events ≥grade 3 in the first 4 weeks before the first
             administration.

        2.Has received anti-angiogenic drugs or other PD-1 / PD-L1 / CTLA-4 antibody therapy or
        other immunotherapy against PD-1 / PD-L1 / CTLA-4.

        14. Has unhealed wounds, fractures, active gastric and duodenal ulcers, positive continuous
        fecal occult blood, ulcerative colitis in the first 4 weeks before the first
        administration.

        15. Has received NMPA approved anti-tumor drugs or immunomodulatory drugs for systemic
        treatment within 2 weeks before the first administration.

        16.Has a history of a hematological system transplantation or organ transplantation.

        17. Has active diverticulitis、peritoneal abscess, intestinal obstruction. 18. Has any
        serious and/or uncontrollable disease. 19. According to the judgement of the investigators,
        there are other factors that may lead to the termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Chen</last_name>
    <phone>0571-88122508</phone>
    <email>chenming@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Chest Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuhong Min</last_name>
      <email>1320722827@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xuhong Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Zhang, Master</last_name>
      <phone>010-69151200</phone>
      <email>zhanglipumch@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Xie, Master</last_name>
      <phone>023-65079227</phone>
      <email>344899525@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yue Xie, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuxi Zhu, Doctor</last_name>
      <phone>023-68811360</phone>
      <email>724513168@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yuxi Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiangcheng Li</last_name>
      <phone>0591-83660063-5152</phone>
      <email>Jianchengli62018@126.com</email>
    </contact>
    <investigator>
      <last_name>Jiangcheng Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Bao, Doctor</last_name>
      <phone>020-86668114</phone>
      <email>baoyong@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yong Bao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yuebei People's Hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suming Pan, Master</last_name>
      <phone>0751-6913383</phone>
    </contact>
    <investigator>
      <last_name>Suming Pan, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhangjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hualin Chen, Doctor</last_name>
      <phone>0759-2387458</phone>
      <email>3549509@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hualin Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital Sun Yat-Sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Liu, Doctor</last_name>
      <phone>0756-2526192</phone>
      <email>85172626@qq.com</email>
    </contact>
    <investigator>
      <last_name>Zhigang Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Long Chen, master</last_name>
      <phone>0771-5310364</phone>
      <email>clong6@126.com</email>
    </contact>
    <investigator>
      <last_name>Long Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050019</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Wang, Doctor</last_name>
      <phone>0311-86095667</phone>
      <email>wangjunzr@163.com</email>
    </contact>
    <investigator>
      <last_name>Jun Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anyang Cancer Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henang</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anping Zheng, Master</last_name>
      <phone>0372-2232091</phone>
      <email>Zhenganping3@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Anping Zheng, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Ge, Doctor</last_name>
      <email>gehong666@126.com</email>
    </contact>
    <investigator>
      <last_name>Hong Ge, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Desheng Hu, Doctor</last_name>
      <phone>027-87670121</phone>
      <email>hds_005@163.com</email>
    </contact>
    <investigator>
      <last_name>Desheng Hu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hui Wang, Doctor</last_name>
      <phone>0731-89762231</phone>
      <email>wanghui710327@163.com</email>
    </contact>
    <investigator>
      <last_name>hui Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rongrong Zhou, Doctor</last_name>
      <phone>0731-89753769</phone>
      <email>664990095@qq.com</email>
    </contact>
    <investigator>
      <last_name>Rongrong Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peiguo Cao, Doctor</last_name>
      <phone>0731-88618285</phone>
      <email>caopeiguo@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Peiguo Cao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huaian First People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changhua Yu, Master</last_name>
      <email>1131603215@qq.com</email>
    </contact>
    <investigator>
      <last_name>Changhua Yu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jifeng Feng, Doctor</last_name>
      <phone>025-83283415</phone>
      <email>fjif@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Jifeng Feng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lianke Liu, Doctor</last_name>
      <phone>025-68306428</phone>
      <email>liulianke@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Lianke Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junhe Li, Doctor</last_name>
      <email>lijunhe88@163.com</email>
    </contact>
    <investigator>
      <last_name>Junhe Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufeng Cheng, Doctor</last_name>
      <phone>0531-82169821</phone>
      <email>qlcyf@163.com</email>
    </contact>
    <investigator>
      <last_name>Yufeng Cheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baoji Central Hospital</name>
      <address>
        <city>Baoji</city>
        <state>Shanxi</state>
        <zip>721008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Geng, Master</last_name>
      <phone>0917-3390834</phone>
      <email>gengyi0917@126.com</email>
    </contact>
    <investigator>
      <last_name>Yi Geng, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Chen, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weihua Yang, Master</last_name>
      <phone>0351-4651623</phone>
      <email>ywh1964@qq.com</email>
    </contact>
    <investigator>
      <last_name>Weihua Yang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Airforce Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lina Zhao, Doctor</last_name>
      <phone>029-84775425</phone>
      <email>zhaolinazln@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Lina Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'anjiantong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhi Zhang, Doctor</last_name>
      <phone>029-85324019</phone>
      <email>zhang9149@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiaozhi Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingsong Pang, Doctor</last_name>
      <email>pangqingsong2013@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingsong Pang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first Hospital of Zhengjiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sengxiang Yan, Doctor</last_name>
      <email>yansenxiang@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Sengxiang Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bing Xia, Doctor</last_name>
      <phone>0571-56006382</phone>
      <email>xb0918@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Bing Xia, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhibing Wu, Doctor</last_name>
      <email>wu_zhibing@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhibing Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaodong Liang, Doctor</last_name>
      <email>lxdctopone@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiaodong Liang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen, Doctor</last_name>
      <phone>0571-88122508</phone>
      <email>chenming@zjcc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongcheng Wu, Master</last_name>
      <phone>0574-87018581</phone>
      <email>doctorwu1967@126.com</email>
    </contact>
    <investigator>
      <last_name>Hongcheng Wu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haihua Yang, Master</last_name>
      <email>yhh93181@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Haihua Yang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Central Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shenpeng Ying</last_name>
      <email>13957608158@139.com</email>
    </contact>
    <investigator>
      <last_name>Shenpeng Ying</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

